
Mirabegron (25mg) + Solifenacin (5mg)
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirbeg-S 25 Tablet ER is a sustained-release oral formulation of a fixed-dose combination of mirabegron (25mg) and solifenacin (5mg) indicated for the treatment of overactive bladder (OAB) symptoms, including urgency, frequency, and incontinence. This once-daily tablet is designed to provide prolonged release of the active ingredients, allowing for a consistent therapeutic effect throughout the day. Mirabegron, a beta-3 adrenergic receptor agonist, works by increasing the bladder's capacity and improving bladder muscle function, while solifenacin, a muscarinic receptor antagonist, reduces the frequency and urgency of bladder contractions. The combination of these mechanisms of action provides a comprehensive approach to managing OAB symptoms, including those associated with urgency incontinence. The tablet is suitable for patients who have not responded adequately to other OAB treatments or who are experiencing intolerable side effects. As with any medication, patients should consult their healthcare provider for guidance on the proper use and potential interactions of Mirbeg-S 25 Tablet ER.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirbeg-S 25 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirbeg-S 25 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirbeg-S 25 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirbeg-S 25 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirbeg-S 25 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirbeg-S 25 Tablet ER

Mirabegron (25mg) + Solifenacin (5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirbeg-S 25 Tablet ER is a sustained-release oral formulation of a fixed-dose combination of mirabegron (25mg) and solifenacin (5mg) indicated for the treatment of overactive bladder (OAB) symptoms, including urgency, frequency, and incontinence. This once-daily tablet is designed to provide prolonged release of the active ingredients, allowing for a consistent therapeutic effect throughout the day. Mirabegron, a beta-3 adrenergic receptor agonist, works by increasing the bladder's capacity and improving bladder muscle function, while solifenacin, a muscarinic receptor antagonist, reduces the frequency and urgency of bladder contractions. The combination of these mechanisms of action provides a comprehensive approach to managing OAB symptoms, including those associated with urgency incontinence. The tablet is suitable for patients who have not responded adequately to other OAB treatments or who are experiencing intolerable side effects. As with any medication, patients should consult their healthcare provider for guidance on the proper use and potential interactions of Mirbeg-S 25 Tablet ER.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirbeg-S 25 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirbeg-S 25 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirbeg-S 25 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirbeg-S 25 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirbeg-S 25 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirbeg-S 25 Tablet ER















